Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 11, Number 8—August 2005


Cost-Benefit of Stockpiling Drugs for Influenza Pandemic

Ran D. Balicer*†Comments to Author , Michael Huerta*, Nadav Davidovitch*†, and Itamar Grotto*†
Author affiliations: *Ministry of Health, Jerusalem, Israel; †Ben-Gurion University of the Negev, Be'er-Sheva, Israel

Main Article

Table A5

Relative risk (RR) and 95% confidence interval (95% CI) for influenza infection and protective efficacy of individual trials with estimate of preexposure (seasonal) prophylaxis

Trial Drug RR (95% CI) Protective efficacy (%) p value for heterogeneity
Hayden et al. (11) Oseltamivir 0.26 (0.13–0.50) 74
Monto et al. (15) Zanamivir 0.32 (0.17–0.63) 68
Overall 0.29 (0.20–0.43) 71 0.643

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO